06/29/2012
Charles River is happy to announce the recent acquisition of Bioscientific Events, a training services company based in the United Kingdom. Bioscientific Events has 20 years of experience in delivering high-quality, accredited courses.
06/08/2012
The newly validated Q175 knock-in mouse is the most true-to-life model of Huntington’s disease.
06/05/2012
Opened on June 4, 2012 at our corporate headquarters, our new, purpose-built Research Animal Diagnostic Services (RADS) laboratory enables us to better serve the laboratory animal community through expanded testing capabilities and streamlined operations.
05/14/2012
By combining long-standing expertise with new research solutions, Charles River facilitates drug development in these important disease areas. Our recently validated rodent models provide rapid, cost-effective methods for evaluating the potential efficacy of novel anti-inflammatory agents targeting COPD or asthma conditions.
05/11/2012
Charles River’s highly experienced group of scientists can provide their expertise to support and accelerate the preclinical development of your cellular therapeutics.
05/10/2012
In response to the growing interest in restoring or preserving not only bone quality but also muscle function in aging or debilitated people, Charles River is expanding our focus beyond the evaluation of bones to now also include other components of the locomotor system. Our new offerings include various novel applications of imaging, biochemical and histomorphometric modalities, as well as electrophysiology measurements (nerve conduction and electromyography) to evaluate the locomotor unit. This expanded focus will allow us to characterize either pharmacologic or adverse effects of xenobiotics.
05/04/2012
Charles River leverages ocular coherence tomography (OCT) technology to offer advanced in vivo microscopic evaluation. This technology helps identify drug toxicity and efficacy by capturing morphologic changes, resulting in a better understanding of a drug’s effect within the eye.
05/01/2012
Funded by the NIH as part of the second phase of the Knockout Mouse Project (KOMP2), the DTCC Consortium is creating a repository of knockout mouse lines and phenotype data as part of an international effort to help researchers develop better models of human disease.
04/24/2012
MucilAir (Epithelix) is an in vitro airway model with morphology and functions mirroring the tracheobronchial epithelium. It has potential applications in inhalation toxicity testing and pharmaceutical lead development, where it may be used to identify potential airway toxicants and facilitate in vivo dose range finding.
04/16/2012
GENEWIZ is a leading global contract research organization, offering DNA sequencing, gene synthesis, molecular biology, genomic, GLP regulatory and bioinformatics services. Their mission is to contribute to the advancement of life sciences and technologies by making research more productive and cost-efficient through their high-quality, scalable services. Clients will benefit from this partnership by receiving Charles River's expertise in cell and viral bank characterization with the added option of GENEWIZ's industry-leading Next Generation Sequencing (NGS) services.